Products
Ebrasodebart Biosimilar Monoclonal Antibody (IGFBP-3 Receptor) for Research
Cat No.: GMP-Bios-INN-1167
Anti-TMEM219/IGFBP-3R therapeutic antibody (Pre-made Ebrasodebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ebrasodebart (development code Ent-001) is a monoclonal antibody targeting TMEM219. It is developed by Enthera for inflammatory bowel diseases, type 1 diabetes mellitus. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1167-1mg | 1mg | 3090 |
| GMP-Bios-INN-1167-10mg | 10mg | |
| GMP-Bios-INN-1167-100mg | 100mg | |
| GMP-Bios-INN-1167-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ebrasodebart biosimilar, Whole mAb, Anti-TMEM219/IGFBP-3R Antibody: Anti-TMEM219/Insulin-like growth factor-binding protein 3 receptor/IGFBP-3R/Transmembrane protein 219 therapeutic antibody |
| INN Name | Ebrasodebart |
| Target | TMEM219/IGFBP-3R |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Enthera |
| Conditions Approved | na |
| Conditions Active | Inflammatory bowel diseases;Type 1 diabetes mellitus |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
